Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Wong

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Transplantation|November 7, 1999
A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipientsB D Kahan, R L Wong, C Carter, et al.
Transplantation|June 27, 1997
Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipientsS Dunn, G Cooney, J Sommerauer, et al.
Transplantation Proceedings|August 1, 1996
Use of Neoral in pediatric renal transplantationR E Ettenger, H T Smith, B Kaiser, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 10, 1999
Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulationG F Cooney, S P Dunn, J Sommerauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1988
Subtypes of helper cells. Non-inflammatory type 1 helper T cellsR L Wong, N H Ruddle, S J Padula, et al.
Biochemical and Biophysical Research Communications|July 14, 1989
Effects of H-7 are not exclusively mediated through protein kinase C or the cyclic nucleotide-dependent kinasesJ T Love, S J Padula, E G Lingenheld, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosisD van der Heijde, A L Pangan, M H Schiff, et al.
Biochemical and Biophysical Research Communications|February 13, 2001
Embryonic XMab21l2 expression is required for gastrulation and subsequent neural developmentG T Lau, O G Wong, P M Chan, et al.
Annals of the Rheumatic Diseases|August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialD van der Heijde, M H Schiff, J Sieper, et al.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Transplantation|November 7, 1999
A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipientsB D Kahan, R L Wong, C Carter, et al.
Transplantation|June 27, 1997
Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipientsS Dunn, G Cooney, J Sommerauer, et al.
Transplantation Proceedings|August 1, 1996
Use of Neoral in pediatric renal transplantationR E Ettenger, H T Smith, B Kaiser, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 10, 1999
Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulationG F Cooney, S P Dunn, J Sommerauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1988
Subtypes of helper cells. Non-inflammatory type 1 helper T cellsR L Wong, N H Ruddle, S J Padula, et al.
Biochemical and Biophysical Research Communications|July 14, 1989
Effects of H-7 are not exclusively mediated through protein kinase C or the cyclic nucleotide-dependent kinasesJ T Love, S J Padula, E G Lingenheld, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosisD van der Heijde, A L Pangan, M H Schiff, et al.
Biochemical and Biophysical Research Communications|February 13, 2001
Embryonic XMab21l2 expression is required for gastrulation and subsequent neural developmentG T Lau, O G Wong, P M Chan, et al.
Annals of the Rheumatic Diseases|August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialD van der Heijde, M H Schiff, J Sieper, et al.
Annals of the Rheumatic Diseases|August 8, 2008
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)P J Mease, P Ory, J T Sharp, et al.
Pageof 6